generic Empagliflozin, used to treat diabetes, related comorbidities, including heart failure, promises to slash therapy costs. Those looking to launch the drug include Mankind Pharma, Torrent, Alkem, Dr Reddy’s and Lupin. Most generic versions will cost Rs 9-14 per tablet, disrupting the high-growth diabetes therapy market valued at nearly Rs 20,000 crore. 10.1cr Indians live with diabetes, most end up paying out-of-pocket due to limited medical reimbursement. The economic burden of diabetes weighs heavily in India, where most patients pay out of pocket due toLimited medical reimbursement, magnifying the challenge. The market was further bolstered by Torrent Pharmaceuticals’ acquisition of three EmPaglif lozin brands from Boehringer Ingelheim last year, sources said. It is estimated that the market size of Em paglif Lozin and its combinations is estimated at Rs 640 crore. Experts highlight its ability to significantly reduce heart failure hospitalisations, slow chronic kidney disease progression and improve survival in both diabetic and non-diabetic patients, though high pricing has long limited access.